Nalbuphine (HCl)

Overview

Nalbuphine (HCl) is a synthetic opiate agonist/antagonist that is chemically related to both naloxone, a narcotic antagonist, and oxymorphone, a potent narcotic analgesic. Used to treat moderate to severe pain associated with acute and chronic medical disorders such as cancer, renal or biliary colic, migraine or vascular headaches, and surgical pain. Another clinical use is obstetrical analgesia during labor and delivery. Some evidence suggests that nalbuphine's respiratory depressant effects do not increase proportionately with increasing doses, thus making this drug safer in patients at risk from respiratory depression. It was approved by the FDA in 1979. Nalbuphin exerts its effects by binding to specific opiate receptors present in the central nervous system, functions as an antagonist at the µ-receptor, however it has agonist action at ?-receptor, Nalbuphine is also an agonist at the d-receptor, but Nalbuphine (HCl) is nalbuphine's action at the ?-receptor that provides analgesia. Actions at the ?-receptors are believed to produce alterations in the perception of pain as well as the emotional response to pain, possibly by altering the release of neurotransmitters from afferent nerves sensitive to painful stimuli.

Categories

• 1 Drugs used in anesthesia
  • 1.3 preoperative medication and sedation

• 1 Drugs used in anesthesia
  • 1.5 Analgesics and opioid antagonists

• 2 Analgesics, antipyretics, NSAIDs, antigout, and antirheumatics
  • 2.2 Opioid analgesics

Page headings

Primary Characterstics

Indications

Pharmacokinetics

Contraindications

Drug Interactions

Side Effects

The severe or irreversible adverse effects of Nalbuphine (HCl), which give rise to further complications include Sinus tachycardia, Urticaria, Hypotension, Hypotension, Orthostatic hypotension, Hypertension, Depression, Sinus bradycardia, Syncope, Respiratory depression.

The symptomatic adverse reactions produced by Nalbuphine (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Dyspnea, Dry mouth, Blurred vision, Pruritus, VertigoX, Sedation, SweatingX, Flushing, Nausea and vomiting, Euphoria, Urinary urgency, Xerostomia, Dry mouth, dizziness.

Dosage

Nalbuphine (HCl)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
10 to 20 mg	15 (15)	12 hourly	IM,IV,SC	For Pain. Frequency may be increased to 3 times if needed.
0.3 to 3 mg/kg	1.6 (1.65)	As recommended.	IV	Over 10 to 15 minutes at induction , Maintanance doses of 250-500ug/kg may be given as intravanous bolus if required .
Paedriatic Dosage (20kg)
0.1 to 0.15 mg/kg	0.12 (0.125)	6 hourly	Intra Muscular	-
0.1 to 0.15 mg/kg	0.12 (0.125)	6 hourly	Intra Venous	-
0.1 to 0.15 mg/kg	0.12 (0.125)	6 hourly	Subcutaneous	-
Neonatal Dosage (3kg)
No data regarding the neonatal dosage details of Nalbuphine (HCl) is available.

High Risk Groups

Warning / Precautions

Storage Conditions

Interference in Pathology

Brands / Trade Names of Nalbuphine (HCl)

Manufacturers of Nalbuphine (HCl) in Pakistan

Back to top